GBA1 deficiency and mutations are related to Gaucher disease, but are also shown to be linked to neurodegenerative events, e.g. in Parkinsons disease. QPS Austria offers the analysis of GCase activity in various in vitro and in vivo models like 1. mouse embryonic fibroblasts (MEFs) of 4L/PS-NA mice and 2. CBE treated D-Line mice, respectively.
Meet us at the WORLD Symposium™ 2019 conference in Orlando, Florida, USA
The QPS Austria Neuropharmacology team will attend the WORLD Symposium 2019 and are pleased to meet you at our booth #215.
Additionally, our scientists are presenting our newest research results in an oral platform presentation and two posters:
Oral Presentation: Tuesday, February 5, 2019, 8:30am
“CBE treatment of alpha-synuclein over-expressing and wildtype mice models Gaucher disease pathology”
Vera Niederkofler, Ewald Auer, David Amschl, Joerg Neddens, Birgit Hutter-Paier
Posters: Wednesday, February 6, 2019, from 4:30-6:30 PM
“Behavioral and histological hallmarks of a mucopolysaccharidosis type IIIA mouse model”
Vera Niederkofler, Ewald Auer, David Amschl, Joerg Neddens, Elisabet Ohlin Sjöström, Susanne Gustavsson, Birgit Hutter-Paier
“Characterization of 4L/PS-NA mice for enzyme activity, substrate concentrations as well as inflammation to model Gaucher disease”
Vera Niederkofler, Ewald Auer, Victoria Schiffer, Tina Loeffler, Joerg Neddens, Staffan Schmidt, Jan Kehr, Birgit Hutter-Paier.
Join us from February 4-8 in Orlando, Florida, USA, at the Hyatt Regency Orlando